Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization

PHASE4CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

July 31, 2018

Study Completion Date

July 31, 2018

Conditions
Choroidal Neovascularization
Interventions
DRUG

0.5mg intravitreal ranibizumab

Patients received ranibizumab (0.5mg, Novartis AG, Basel, Switzerland) via a pars plana transcleral injection through 30-gauge needle at 3.5 to 4mm of inferotemporal limbus. Levofloxacin eye drops ( Cravit Eye Drops, Santen, Japan) was instilled 4 times a day in the study eye before the treatment at least 1 day. Povidone-iodine (5%, Luofushan Pharmaceutical Co., China) was applied to the conjunctiva bulbi and the fornices for at least 3 minutes before injection. Patients were instructed to continue the levofloxacin eye drops 4 times a day for 3 days

Trial Locations (1)

510060

ZhongShan Ophthalmic Center, Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Zhongshan Ophthalmic Center, Sun Yat-sen University

OTHER

NCT03042871 - Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization | Biotech Hunter | Biotech Hunter